Spots Global Cancer Trial Database for Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

Official Title: Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma

Study ID: NCT02301494

Conditions

Mycosis Fungoides

Interventions

3.75% Imiquimod Cream

0.1% Fluocinonide Cream

Study Description

Brief Summary: This study is being conducted by Brian Poligone, MD PhD. The purpose of this study is to determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).

Detailed Description: The purpose of the study is to compare the safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage CTCL.